Tocilizumab in patients with COVID-19: which patient, time, and dose?
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Text and Data Mining valid from 2021-07-15
Version of Record valid from 2021-07-15
2 June 2021
10 July 2021
15 July 2021
The authors declare that they have no conflict of interest with this work<b>.</b>
Free to read:
This content has been made available to all.